Updates on COVID-19 (including visitor restrictions and mask requirements), monkeypox and flu. See Communicable Disease Updates

LUX-Dx Insertable Cardiac Monitor Remote Programming and Performance Study

Trial ID:
John Rogers, M.D.
This is a post-market study to collect information on the safety and effectiveness of the remote programming feature of the FDA approved LUX-Dx Insertable Cardiac Monitor system in patients who are indicated to receive the device to continuously monitor their heart rhythm as part of clinical care.

Inclusion Criteria

Patients must:
  • Be 18 years or older
  • Be clinically indicated to be implanted with the LUX-Dx ICM
  • Willing and able to be followed remotely via the ICM patient mobile app
  • Meet all other eligibility criteria

Exclusion Criteria

Patients must not:
  • Be indicated for or currently implanted with an implantable cardiac device
  • Be pregnant at the time of study enrollment
  • Be currently enrolled in another clinical study

Additional Info

  • All patients will be implanted with the LUX-Dx ICM according to clinical care. Subjects will have study related follow-up visits (virtual or telephone) at 6 and 12 months. Total study duration is expected to be 12 months.

Contact Info:

  • CRS Leadership
  • CRSLeadership@scrippshealth.org